[Adverse immunologic effects of immunomodulators revealed in experiment and ways to their surmounting].
Immunomodulators licopid (synthetic analogue of muramylpeptide) and purified staphylococcal toxoid (PST) in some variants of experiments on mice caused adverse immunologic effects: enhancement of virus-induced immunosupression, shift from latent immunosupression (revealed only by low, but not standard, doses of test-antigen) to manifested one. Described adverse effects are not a contraindication for use of the studied drugs in practice. Their adverse effects were revealed only after single inoculation, whereas in clinical conditions PST and licopid are used by courses with duration of 5-7 and 10 days respectively. Our experiments show that inoculation of suppressive doses of the preparations repeated by 2-4 times can prevent the shift from latent to manifested immunosupression. Enhancement of immunosupression was not observed in case of combined administration of suppressive doses of PST and adjuvant dose of licopid.
Semenova
I B
IB
D000119:Acetylmuramyl-Alanyl-Isoglutamine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000276:immunology; D000818:Animals; D000921:Antibody-Producing Cells / Q000276:immunology; D004306:Dose-Response Relationship, Immunologic; D004334:Drug Administration Schedule; D002141:Encephalitis Virus, California / Q000276:immunology; D004770:Enterovirus / Q000276:immunology; D016867:Immunocompromised Host / Q000276:immunology*; D007155:Immunologic Factors / Q000008:administration & dosage / Q000009:adverse effects*; D007165:Immunosuppression Therapy; D007274:Injections, Intraperitoneal; D051379:Mice; D008807:Mice, Inbred BALB C; D008808:Mice, Inbred CBA; D013208:Staphylococcal Toxoid / Q000008:administration & dosage / Q000009:adverse effects* / Q000276:immunology; D013997:Time Factors
D007155:Immunologic Factors; D013208:Staphylococcal Toxoid; C089161:glikopin; D000119:Acetylmuramyl-Alanyl-Isoglutamine